Search details
1.
RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature
; 526(7574): 583-6, 2015 Oct 22.
Article
in English
| MEDLINE | ID: mdl-26466569
2.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
N Engl J Med
; 373(5): 428-37, 2015 Jul 30.
Article
in English
| MEDLINE | ID: mdl-26222558
3.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Nature
; 467(7315): 596-9, 2010 Sep 30.
Article
in English
| MEDLINE | ID: mdl-20823850
4.
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.
Proc Natl Acad Sci U S A
; 110(14): 5689-94, 2013 Apr 02.
Article
in English
| MEDLINE | ID: mdl-23493555
5.
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
Proc Natl Acad Sci U S A
; 106(1): 262-7, 2009 Jan 06.
Article
in English
| MEDLINE | ID: mdl-19116277
6.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Proc Natl Acad Sci U S A
; 105(8): 3041-6, 2008 Feb 26.
Article
in English
| MEDLINE | ID: mdl-18287029
7.
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
JAMA Oncol
; 7(9): 1343-1350, 2021 Sep 01.
Article
in English
| MEDLINE | ID: mdl-34236401
8.
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Nat Biotechnol
; 23(2): 201-7, 2005 Feb.
Article
in English
| MEDLINE | ID: mdl-15685167
9.
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Structure
; 12(12): 2233-47, 2004 Dec.
Article
in English
| MEDLINE | ID: mdl-15576036
10.
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Cancer Discov
; 5(6): 668-79, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25847190
11.
Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.
J Pharm Sci
; 102(3): 967-81, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23280631
12.
Phosphodiesterase-4 as a potential drug target.
Expert Opin Ther Targets
; 9(6): 1283-305, 2005 Dec.
Article
in English
| MEDLINE | ID: mdl-16300476
13.
Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents.
Bioorg Med Chem Lett
; 14(14): 3793-7, 2004 Jul 16.
Article
in English
| MEDLINE | ID: mdl-15203164
Results
1 -
13
de 13
1
Next >
>>